Electrophysiologic effects and outcomes of sympatholysis in patients with recurrent ventricular arrhythmia and structural heart disease

• Published in: Journal of cardiovascular electrophysiology 2019-09, Vol.30 (9), p.1499-1507
• Main Authors: Cai, Cheng, Dai, Ming‐Yan, Tian, Ying, Zhang, Pei, Wittwer, Erica D., Rho, Richard H., Kapa, Suraj, McLeod, Christopher J., Mulpuru, Siva K., Lee, Hon‐Chi, Ackerman, Michael J., Asirvatham, Samuel J., Munger, Thomas M., Chen, Ming‐Long, Friedman, Paul A., Cha, Yong‐Mei
• Format: Article
• Language: English
• Subjects: Arrhythmia; autonomic nervous system; Cardiac arrhythmia; cardiac sympathetic denervation; Cardiovascular disease; Cardiovascular diseases; Congestive heart failure; Coronary artery disease; Denervation; Electrocardiography; Heart; Heart rate; Heart transplantation; Recovery time; Refractory period; Stellate ganglion; stellate ganglion block; Tachycardia; Ventricle; ventricular arrhythmia
• ISSN: 1045-3873; 1540-8167
• DOI: 10.1111/jce.14030

Introduction Autonomic modulation has been used as a therapy to control recurrent ventricular arrhythmia (VA). This study was to explore stellate ganglion block (SGB) effect on cardiac electrophysiologic properties and evaluate the long‐term outcome of cardiac sympathetic denervation (CSD) for patients with recurrent VA and structural heart disease (SHD). Materials and Methods Patients who had recurrent VA due to SHD were enrolled prospectively. Electrophysiologic study and ventricular tachycardia (VT) induction were performed before and after left and right SGB. VA burden and long‐term outcomes were assessed for a separate patient group who underwent left or bilateral CSD for drug‐refractory VA due to SHD. Results Electrophysiologic study of nine patients showed that baseline mean (SD) corrected sinus node recovery time (cSNRT) increased from 320.4 (73.3) ms to 402.9 (114.2) ms after left and 482.4 (95.7) ms after bilateral SGB (P = .03). SGB did not significantly change P‐R, QRS, and Q‐T intervals and ventricular effective refractory period, nor did the inducibility of VA. Nineteen patients underwent left (n = 14) or bilateral (n = 5) CSD. CSD reduced VA burden and appropriate ICD therapies from a median (interquartile range) of 2.5 (0.4‐11.6) episodes weekly to 0.1 (0.0‐2.4) episodes weekly at 6‐month follow‐up (P = .002). Three‐year freedom from orthotopic heart transplant (OHT) and death was 52.6%. New York Heart Association functional class III/IV and VT rate less than 160 beats per minute were predictors of recurrent VA, OHT, and death. Conclusion SGB increased cSNRT without changing heart rate. CSD was more beneficial for patients with mild‐to‐moderate heart failure and faster VA.